Literature DB >> 23435474

The opportunity cost of androgen suppression in locally advanced prostate cancer.

Phillip J Gray1, Jason A Efstathiou, William U Shipley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23435474      PMCID： PMC3739662          DOI： 10.1038/aja.2012.166

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  14 in total

1.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Authors:  Nancy L Keating; A James O'Malley; Stephen J Freedland; Matthew R Smith
Journal:  J Natl Cancer Inst       Date:  2009-12-07       Impact factor: 13.506

2.  Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer.

Authors:  James A Talcott; Carl Rossi; William U Shipley; Jack A Clark; Jerry D Slater; Andrzej Niemierko; Anthony L Zietman
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

3.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

4.  Duration of androgen suppression in the treatment of prostate cancer.

Authors:  Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

5.  Quality of life and satisfaction with outcome among prostate-cancer survivors.

Authors:  Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

6.  Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

7.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

8.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

Authors:  Mack Roach; Kyounghwa Bae; Joycelyn Speight; Harvey B Wolkov; Phillip Rubin; R Jeffrey Lee; Colleen Lawton; Richard Valicenti; David Grignon; Miljenko V Pilepich
Journal:  J Clin Oncol       Date:  2008-01-02       Impact factor: 44.544

9.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

Authors:  Eric M Horwitz; Kyounghwa Bae; Gerald E Hanks; Arthur Porter; David J Grignon; Harmar D Brereton; Varagur Venkatesan; Colleen A Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

10.  Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.